CN105999232A - 包含升麻皂苷的药物组合物及其应用 - Google Patents
包含升麻皂苷的药物组合物及其应用 Download PDFInfo
- Publication number
- CN105999232A CN105999232A CN201610629384.2A CN201610629384A CN105999232A CN 105999232 A CN105999232 A CN 105999232A CN 201610629384 A CN201610629384 A CN 201610629384A CN 105999232 A CN105999232 A CN 105999232A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- saponin
- rhizoma cimicifugae
- procalcitonin
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 20
- 229930182490 saponin Natural products 0.000 title claims abstract description 20
- 150000007949 saponins Chemical class 0.000 title claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 241000906579 Actaea cimicifuga Species 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 15
- 108010048233 Procalcitonin Proteins 0.000 claims abstract description 11
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 229960005339 acitretin Drugs 0.000 claims description 5
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
- 229960004015 calcitonin Drugs 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241000906543 Actaea racemosa Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000905376 Actaea dahurica Species 0.000 description 1
- 241000906577 Actaea heracleifolia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003126 acitretin group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
抑制率(%) | MCF-7 | Hela | skov3 |
组1 | 10.3±1.1 | 14.2±1.3 | 7.4±1.1 |
组2 | 25.2±1.2 | 28.5±1.6 | 17.3±1.3 |
组3 | 1.3±0.3 | 1.7±0.4 | 0.5±0.2 |
组4 | 3.6±0.5 | 4.4±0.5 | 1.1±0.3 |
组5 | 36.4±1.6 | 30.2±1.8 | 18.4±0.9 |
组6 | 48.9±2.1 | 31.7±1.9 | 19.5±1.1 |
组7 | 34.3±1.9 | 29.9±1.5 | 18.9±1.2 |
组8 | 55.1±2.3 | 32.6±2.1 | 19.2±0.9 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610629384.2A CN105999232B (zh) | 2016-08-03 | 2016-08-03 | 包含升麻皂苷的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610629384.2A CN105999232B (zh) | 2016-08-03 | 2016-08-03 | 包含升麻皂苷的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105999232A true CN105999232A (zh) | 2016-10-12 |
CN105999232B CN105999232B (zh) | 2018-07-03 |
Family
ID=57133706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610629384.2A Expired - Fee Related CN105999232B (zh) | 2016-08-03 | 2016-08-03 | 包含升麻皂苷的药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105999232B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114432368A (zh) * | 2022-02-28 | 2022-05-06 | 哈尔滨博达森虎医药科技有限公司 | 一种治疗自身免疫性疾病的包含升麻皂苷的药物组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052471A1 (en) * | 1999-12-22 | 2002-05-02 | Dade Behring Marburg Gmbh. | Human procalcitonin and the preparation and use thereof |
CN101730711A (zh) * | 2007-06-22 | 2010-06-09 | 法国古斯塔夫鲁西研究院 | 降钙素原前体抗原t表位 |
-
2016
- 2016-08-03 CN CN201610629384.2A patent/CN105999232B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052471A1 (en) * | 1999-12-22 | 2002-05-02 | Dade Behring Marburg Gmbh. | Human procalcitonin and the preparation and use thereof |
CN101730711A (zh) * | 2007-06-22 | 2010-06-09 | 法国古斯塔夫鲁西研究院 | 降钙素原前体抗原t表位 |
Non-Patent Citations (2)
Title |
---|
田泽,等: "兴安升麻地上和地下部分总苷生物活性比较", 《中药材》 * |
赵雁,等: "阿维A联合克拉霉素对裸鼠移植瘤生长及肿瘤血管生成的影响", 《中华皮肤科杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114432368A (zh) * | 2022-02-28 | 2022-05-06 | 哈尔滨博达森虎医药科技有限公司 | 一种治疗自身免疫性疾病的包含升麻皂苷的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN105999232B (zh) | 2018-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101352557B (zh) | 治疗胃癌的中药制剂及其制备方法 | |
CN102008650B (zh) | 一种治疗肿瘤的复方中药制剂及其制备方法 | |
CN103861079A (zh) | 一种清热止痛消瘤中药组合物 | |
CN106668041A (zh) | 重楼皂苷vi在制备抗肺癌药物中的应用 | |
CN105999232A (zh) | 包含升麻皂苷的药物组合物及其应用 | |
CN103142934B (zh) | 一种抗肺癌和肝癌的中药组合物 | |
CN106110305B (zh) | 包含升麻皂苷的药物制剂及其应用 | |
CN104189597A (zh) | 一种治疗胃热壅盛型急性乳腺炎的中药及其制备方法 | |
CN103933472B (zh) | 一种抗肝癌和肺癌的中药组合物 | |
Ydyrys | An Overview of Medical Uses and Chemical Composition of Arctium tomentosum mill. | |
CN103142935A (zh) | 一种抗肝癌和肺癌的中药组合物 | |
CN103536862B (zh) | 防治胃癌的益气活血复方中药制剂及其制备方法 | |
CN103169844B (zh) | 具有抗肺癌和肝癌作用的中药组合物 | |
Abuarab et al. | Immunomodulatory and anticancer activities of barley bran grown in Jordan: An in vitro and in vivo study | |
CN102526283A (zh) | 一种增强免疫力、缓解体力疲劳、抗肿瘤功能的保健药物配方 | |
CN100586443C (zh) | 一种红花桑寄生提取物的应用 | |
CN100381129C (zh) | 一种抗肿瘤的动物药及其制备方法 | |
CN104707101A (zh) | 一种抗肝癌和肺癌的中药组合物及用途 | |
CN100411663C (zh) | 复方中药抗癌散及其制备方法 | |
CN103169845B (zh) | 一种具有抗肝癌和肺癌作用的中药组合物 | |
CN103566058B (zh) | 一种双青组合药物、制备方法及其应用 | |
US10960039B2 (en) | Composition, preparation method and use of the same in manufacture of a product for relieving thyroid nodules | |
CN105663551A (zh) | 胰腺癌患者术后服用的中药制剂及制法 | |
CN105412609A (zh) | 一种治疗肝郁脾虚型溃疡性结肠炎的中药及制备方法 | |
Wei et al. | Advances in the exploration of adjuvant therapy of colon cancer with Chinese medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171121 Address after: 150040 Heping Road, Xiangfang District, Heilongjiang, Harbin, China, 24 Applicant after: Heilongjiang University of Chinese Medicine Address before: 150040 Heping Road, Xiangfang District, Heilongjiang, Harbin, China, 24 Applicant before: Su Yang |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Xueying Inventor after: Jin Shuang Inventor before: Su Yang Inventor before: Kuang Haixue Inventor before: Wu Lun Inventor before: Wang Qiuhong |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180703 Termination date: 20190803 |